China Universal Asset Management Company’s Ascendis Pharma A/S ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.61M Sell
9,798
-1,127
-10% -$263K 0.16% 104
2026
Q1
$2.5M Buy
10,925
+921
+9% +$206K 0.19% 90
2025
Q4
$2.13M Sell
10,004
-663
-6% -$137K 0.16% 105
2025
Q3
$2.12M Sell
10,667
-1,519
-12% -$283K 0.18% 108
2025
Q2
$2.1M Buy
12,186
+73
+0.6% +$11.9K 0.2% 106
2025
Q1
$1.89M Sell
12,113
-676
-5% -$96.6K 0.18% 113
2024
Q4
$1.76M Buy
12,789
+1,647
+15% +$217K 0.16% 112
2024
Q3
$1.66M Buy
11,142
+4,338
+64% +$586K 0.18% 107
2024
Q2
$928K Sell
6,804
-4,216
-38% -$574K 0.13% 108
2024
Q1
$1.67M Buy
11,020
+4,385
+66% +$626K 0.21% 91
2023
Q4
$836K Buy
6,635
+5,173
+354% +$516K 0.16% 120
2023
Q3
$137K Buy
1,462
+714
+95% +$66.8K 0.04% 172
2023
Q2
$66.8K Sell
748
-23
-3% -$2K 0.02% 173
2023
Q1
$82.7K Buy
771
+204
+36% +$23.3K 0.03% 134
2022
Q4
$69.2K Buy
567
+47
+9% +$5.46K 0.03% 129
2022
Q3
$54K Buy
+520
New +$49.3K 0.02% 122

Other funds holding ASND

China Universal Asset Management Company's ASND Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Ascendis Pharma A/S (ASND) stake by 10% in Q2 2026, selling an estimated $263K and leaving 9,798 shares worth $2.61M. The position accounts for 0.16% of the portfolio, ranked #104.

China Universal Asset Management Company first reported a position in ASND in Q3 2022 and has held it in 16 quarters since. 34 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • China Universal Asset Management Company held 9,798 shares of Ascendis Pharma A/S worth $2.61M as of Q2 2026.
  • China Universal Asset Management Company sold 1,127 Ascendis Pharma A/S shares in Q2 2026, an estimated $263K.
  • Ascendis Pharma A/S made up 0.16% of China Universal Asset Management Company's portfolio in Q2 2026, its #104 holding.
  • China Universal Asset Management Company first reported a position in Ascendis Pharma A/S in Q3 2022 and has held it in 16 quarters since.
  • 34 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.